Maze Therapeutics, Inc.

MAZE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
Assets
Cash & Equivalents$197$29$100
Short-Term Investments$0$0$0
Receivables$0$0$0
Inventory$0$0$0
Other Curr. Assets$5$5$6
Total Curr. Assets$202$34$106
Property Plant & Equip (Net)$30$35$41
Goodwill$0$0$0
Intangibles$0$0$0
Long-Term Investments$1$1$1
Tax Assets$0$0$0
Other NC Assets$8$1$1
Total NC Assets$39$37$44
Other Assets$0$0$0
Total Assets$241$72$150
Liabilities
Payables$2$2$2
Short-Term Debt$5$4$4
Tax Payable$0$0$0
Deferred Revenue$0$0$0
Other Curr. Liab.$14$10$15
Total Curr. Liab.$21$16$21
LT Debt$22$45$28
Deferred Rev, NC$0$0$0
Deferred Tax Liab, NC$0$0$0
Other NC Liab.$1$0$0
Total NC Liab.$23$45$28
Other Liabilities$0$0$0
Cap. Leases$27$30$32
Total Liabilities$44$61$49
Equity
Pref Stock$508$384$384
Common Stock$0$0$0
Retained Earnings-$358-$396-$295
AOCI$0$0$0
Other Equity$47$22$13
Total Equity$197$10$101
Supplemental Information
Minority Interest$0$0$0
Total Liab. & Tot. Equity$241$72$150
Net Debt-$170$20-$68
Maze Therapeutics, Inc. (MAZE) Financial Statements & Key Stats | AlphaPilot